Combining conventional therapy with immunotherapy: A risky business?

被引：26

作者：

Coosemans, A. ^{[1
,2
]}

Vankerckhoven, A. ^{[2
]}

Baert, T. ^{[2
,3
]}

Boon, L. ^{[4
]}

Ruts, H. ^{[2
]}

Riva, M. ^{[2
]}

Blagden, S. ^{[5
]}

Delforge, M. ^{[6
]}

Concin, N. ^{[7
]}

Mirza, M. R. ^{[8
]}

Ledermann, J. A. ^{[9
]}

du Bois, A. ^{[3
]}

Vergote, I ^{[1
,2
,10
]}

机构：

[1] UZ Leuven, Dept Gynaecol & Obstet, Leuven Canc Inst, Leuven, Belgium

[2] Katholieke Univ Leuven, Lab Tumour Immunol & Immunotherapy, Dept Oncol, ImmunOvar Res Grp, Leuven, Belgium

[3] KEM, Dept Gynaecol & Gynaecol Oncol, Essen, Germany

[4] Bioceros BV, Utrecht, Netherlands

[5] Univ Oxford, Early Phase Clin Trials Unit, Dept Oncol, Oxford, England

[6] UZ Leuven, Dept Haematol, Leuven Canc Inst, Leuven, Belgium

[7] Med Univ Innsbruck, Dept Gynaecol & Obstet, Innsbruck, Austria

[8] Copenhagen Univ Hosp, Rigshosp, Copenhagen, Denmark

[9] UCL, UCL Canc Inst, London, England

[10] Katholieke Univ Leuven, Lab Gynecol Oncol, Dept Oncol, Leuven, Belgium

来源：

EUROPEAN JOURNAL OF CANCER | 2019年 / 113卷

关键词：

Immunotherapy; Tumor immunology; Chemotherapy; Combination; Survival; TUMOR MICROENVIRONMENT; CHEMOTHERAPY; OVARIAN; CANCER; PROGRESSION;

D O I：

10.1016/j.ejca.2019.02.014

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Because of the failure of immunotherapy as single agent in a number of cancers, current clinical trials are focusing on combining immunotherapy with other therapies. The most frequently chosen combination for immunotherapy is chemotherapy. However, almost no preclinical data on this combination is available. Some studies even showed a dismal effect of combining chemotherapy with immunotherapy. Taken into account that each of the therapies chosen in a combination will influence the cancer cells but also immune effector cells as well as immunosuppressive cells, and that these three partners will also interact with each other, launching a combination to the patient without proper immune monitoring and preclinical evidence might be devastating. (C) 2019 Elsevier Ltd. All rights reserved.

引用

页码：41 / 44

页数：4

共 50 条

[1] Prospects for combining targeted and conventional cancer therapy with immunotherapy
Gotwals, Philip
Cameron, Scott
Cipolletta, Daniela
Cremasco, Viviana
Crystal, Adam
Hewes, Becker
Mueller, Britta
Quaratino, Sonia
Sabatos-Peyton, Catherine
Petruzzelli, Lilli
Engelman, Jeffrey A.
Dranoff, Glenn
NATURE REVIEWS CANCER, 2017, 17 (05) : 286 - 301
[2] Prospects for combining targeted and conventional cancer therapy with immunotherapy
Philip Gotwals
Scott Cameron
Daniela Cipolletta
Viviana Cremasco
Adam Crystal
Becker Hewes
Britta Mueller
Sonia Quaratino
Catherine Sabatos-Peyton
Lilli Petruzzelli
Jeffrey A. Engelman
Glenn Dranoff
Nature Reviews Cancer, 2017, 17 : 286 - 301
[3] COMBINING IMMUNOTHERAPY WITH RADIATION THERAPY
Formenti, S.
Golden, E.
Adams, S.
Demaria, S.
RADIOTHERAPY AND ONCOLOGY, 2012, 104 : 21 - 22
[4] IS HUMAN GENE-THERAPY RISKY BUSINESS
BARRETT, MJ
HUMAN GENE THERAPY, 1990, 1 (01) : 105 - 106
[5] VEGF therapy: risky business for established plaques?
Kadl, Alexandra
Leitinger, Norbert
BLOOD, 2007, 109 (01) : 2 - 3
[6] Abscopal Effect when Combining the conventional Tadiation with Immunotherapy
Hindemith, M.
Seyer, C.
Liebmann, A.
STRAHLENTHERAPIE UND ONKOLOGIE, 2018, 194 : S114 - S114
[7] Combining cancer immunotherapy and targeted therapy
Ribas, Antoni
Wolchok, Jedd D.
CURRENT OPINION IN IMMUNOLOGY, 2013, 25 (02) : 291 - 296
[8] Combining immunotherapy with classical anticancer therapy
Zwierzina, H.
ANNALS OF ONCOLOGY, 2008, 19 : 252 - 255
[9] The Promise of Combining Radiation Therapy With Immunotherapy
Jagodinsky, Justin C.
Harari, Paul M.
Morris, Zachary S.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (01): : 6 - 16
[10] Risky business: target choice in adoptive cell therapy
Morgan, Richard A.
BLOOD, 2013, 122 (20) : 3392 - 3394

← 1 2 3 4 5 →